ERJ Open Research (Jan 2024)

Bronchodilator responsiveness in children with primary ciliary dyskinesia

  • Elias Seidl,
  • Dvir Gatt,
  • Wallace B. Wee,
  • David Wilson,
  • Felix Ratjen,
  • Hartmut Grasemann

DOI
https://doi.org/10.1183/23120541.00611-2023
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

Background Reversible airway obstruction is common in children with primary ciliary dyskinesia. However, the diagnostic value of adding bronchodilator (BD) response testing to routine spirometry is unclear. Methods This is a retrospective analysis of pulmonary function test results obtained from children with primary ciliary dyskinesia seen as outpatients at the Hospital for Sick Children, Toronto. Spirometry results were collected for every appointment with BD response testing (“Visit”, with pre-BD and post-BD measurements) as well as for the previous (“Baseline”) and following (“Follow-up”) encounters. Results A positive BD response was seen in 86 out of 474 (18.1%) of the pulmonary function tests from 82 children with primary ciliary dyskinesia. BD responsiveness was associated with a significant absolute change (±sd) in % predicted forced expiratory volume in 1 s (FEV1) from Baseline to Visit pre-BD (−6.5±10.3%, p<0.001), but not from Baseline to Follow-up (0.4±10.8, p=0.757). Antimicrobial therapy was initiated more commonly following a Visit with a positive BD response (OR 3.8, 95% CI 2.2–6.6) compared to no BD response. Children with a positive BD response had a greater annual decline in FEV1 % predicted compared to those with no BD response (−0.9% per year versus −0.5% per year, p<0.001). The annual decline in FEV1 % predicted was greater in children with multiple compared to one measured positive BD responses (−1.3% per year versus −0.6% per year, p<0.001) and in those not treated with antibiotic therapy following a positive BD response compared to those treated with antibiotics (−1.1% versus −0.6%, p<0.001). Conclusion A positive BD response in children with primary ciliary dyskinesia may help identify those at risk for accelerated lung disease progression.